Skip to main content

Table 5 Incidence of dose delays

From: Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety

Study

Dose delays

Balducci [19]

 

Combined CHOP and R-CHOP Q2W

Combined CHOP and R-CHOP Q3W

<  65 years

(n = 32)

65–75 years

(n = 30)

>  75 years

(n = 0)

Overall

(n = 62)

<  65 years (n = 27)

65–75 years

(n = 78)

75 years

(n = 32)

Overall

(n = 137)

Dose delay

18.8

30.0

–

24.2

25.9

26.9

28.1

27.0

%, 95 CI

7.2–36.4

14.7–49.4

–

14.2–36.7

11.1–46.3

17.5–38.2

13.7–46.7

19.8–35.3

Hecht [23]

 

Placebo (n = 118)

Pegfilgrastim (n = 123)

p value

Dose delays, % (95% CI), any reason

36.5 (27.9–45.1)

19.6 (12.7–26.5)

p = 0.003

Dose delay, % (95% CI), because of neutropenia

19.5 (12.4–26.6)

4.1 (0.6–7.6)

p < 0.001

Hendlera [24]

 

Overall patients

Group A

Group B

Group C

Group D

Total treated, n (%)

231 (100)

84 (36.3)

26 (11.3)

64 (27.7)

57 (24.7)

Treatment delaysb

35 (3.8)

17 (5.0)

1 (0.9)

10 (3.9)

7 (3.0)

Kourlaba [25]

 

Filgrastim (95% CI)

Pegfilgrastim (95% CI)

p value

Treatment delays (>  2 days), % (95% CI)

42.0 (37.7–46.3)

27.6 (23.8–31.6)

p < 0.001

Lane [27]

 

Pegfilgrastim

G-CSF

p value

Delay in next cycle, %

44.4

46.5

p = 0.75

Lugtenburg [28]

 

R-CHOP-14

R-CHOP-21

 

<  65 years (n = 241)

≥ 65 years (n = 168)

<  65 years (n = 343)

≥ 65 years (n = 361)

Dose delays (per regimen), %

44

61

37

48

PP per intervention, %

54

58

17

32

Patients with a dose delay treated with pegfilgrastim, %

23.8

35

6.3

15

Ng [29]

 

CHOP-14 (n = 60)

CHOP-21 (n = 72)

p value

Dose delay complications,c %

16.7

19.4

p = 0.8

Pinter [30]

Dose delays

Pegfilgrastim

Placebo

 

FOLFOX-treated patients, % (n) [95% CI]

21.3 (44) [15.9–27.5]

16.9 (35) [12.1–22.7]

FOLFIRI-treated patients, % (n) [95% CI]

27.8 (60) [21.9–34.3]

22.8 (49) [17.4–29.0]

Low-dose patients, % (n) [95% CI]

27.0 (47) [20.6–34.3]

16.9 (27) [11.4–23.6]

High-dose patients, % (n) [95% CI]

22.9 (57) [17.8–28.6]

21.8 (57) [16.9–27.2]

Skarlos [31]

 

Filgrastim (n = 107)

Pegfilgrastim (n = 107)

p value

 

Treatment delays (>  2 days), n (%)

65 (61%)

61 (57%)

p = 0.65

  1. aGroup A: G-CSF 300 μg 8 consecutive administrations during days 3–10; group B: G-CSF 300 μg consecutive administrations between days 3–7; group C: G-CSF administrations every other day for days 5, 7, 9 and 11; and group D: one administration of pegfilgrastim 6 mg on day 2
  2. bThe treatment delays in all the groups were due to febrile neutropenia events and nonhematological toxicity
  3. cMeasured per cycle
  4. CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, CI confidence interval, FOLFIRI 5-fluorouracil, leucovorin, and irinotecan, FOLFOX 5-fluorouracil, leucovorin, and oxaliplatin, G-CSF granulocyte colony-stimulating factor, PP prophylactic pegfilgrastim, Q2W biweekly, Q3W every 3 weeks, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us